|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 2001;71:1400-1401
© 2001 The Society of Thoracic Surgeons
a Clinic for Cardiovascular Surgery, University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
e-mail: Jan.Christenson{at}hcge.ch
To the Editor
I have with great interest read the comments by Dr Baskett and his colleagues regarding my article [1]. It is absolutely correct, as stated by Dr Baskett, that we have demonstrated, in a prospective randomized trial, a significantly higher hospital mortality rate in patients who did not receive preoperative intraaortic balloon pump (IABC) therapy (control group) compared to similar high-risk patients who received preoperative IABC therapy [2]. It should, however, be noted that at the time there were no other studies published that could confirm these results. Because of lack of supportive studies from other institutions together with a rather small number of control patients used in the first trial (n = 30) and the need to evaluate optimal timing for the preoperative IABC therapy, it was decided to perform a second prospective randomized trial including a control group (patients not receiving preoperative IABC therapy). This issue was thoroughly discussed by the local Ethical Committee, which granted permission for the trial, and second trial was undertaken [3]. Based on the experience from the first trial, the cut-off level for preoperative LVEF was lowered from less than 0.40 to less than 0.30. Since at least two high-risk criteria were requested for inclusion in both studies there were no fundamental differences between patients used for the combined study on the economical impact of preoperative IABC therapy that would have any impact of the analysis done [1]. In conclusion, the combined study did not only demonstrate a highly significant decrease in hospital mortality when preoperative IABC therapy was used, but also decreased postoperative morbidity as well as a significantly shortened ICU and hospital stay, and a significant difference in procedural cost [1]. Further use of a control group in this context (high-risk coronary patients) is therefore no longer acceptable.
References
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |